Stockreport

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia [Yahoo! Finance]

Reviva Pharmaceuticals Holdings, Inc.  (RVPH) 
PDF - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Top [Read more]